FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Roche news from FiercePharma

News

Drugmakers resist U.K. price goals

Drug companies are standing their ground in price negotiations with the U.K. government. Pharma is offering to cut the U.K.'s drug bill by roughly half the government's goal, The Daily Telegraph Read more...

Drugmakers fighting for best U.K. deal

As the U.K. nears a long-term drug-pricing deal with pharma firms, drugmakers are grousing about the fact that the government decided to renegotiate at all. You'll recall that late last year, the Read more...
Tags: Astrazeneca   Roche  

SPOTLIGHT: NICE rejects Roche drug as too costly

Roche's lung cancer med Tarceva got the goodbye gong from the U.K.'s National Institute for Clinical Excellence, which ruled that the drug wasn't a cost-effective option for treating non-small cell Read more...
Tags: Roche   Tarceva   lung cancer  

Roche, Cipla trade jabs on Tarceva

We turn to India for updates on another cancer-drug battle, this one between Roche's brand-name Tarceva and Cipla's copycat version, Erlocip. A Roche distributor tattled to India's Drug Controller Read more...

Pfizer, Roche suffer as big drugs falter

Today's earnings roundup is a snapshot of pharma's challenges--generic Read more...

Falling dollar, falling drugmaker prices

Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...

FDA probes Roche, Novartis meds

The transplant drug probe is widening. FDA says it's identified 16 cases of an often-fatal neurological disease among patients taking Roche's CellCept drug, used to prevent organ rejection. The Read more...

Roche appeals Mircera injunction

Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring Read more...

What did Vasella see in Alcon?

Just why would Novartis pay $11 billion for one-fourth of an eye-care company and promise another $28 Read more...
Tags: Daniel Vasella   buyouts   Alcon   Roche   Novartis  

SPOTLIGHT: Novartis: No more deals, no Roche sale

Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for Read more...
Tags: Novartis   Roche   Daniel Vasella   Alcon  

Press Releases

PRESS RELEASE: Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic

Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic Summary: An IND has Been Filed With the FDA for the Fourth Genmab Antibody Developed Under the Company's Collaboration with Read more...

PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing

FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more...

PRESS RELEASE: Roche Confirms Commencement of Due Diligence with Ventana

Roche Confirms Commencement of Due Diligence with Ventana Roche confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it Read more...

PRESS RELEASE: Ventana Enters into Confidentiality Agreement with Roche

Ventana Enters into Confidentiality Agreement with Roche TUCSON, Ariz. -- Nov. 13, 2007--Ventana Medical Systems, the global leader in tissue-based cancer diagnostics, today announced it has entered Read more...

PRESS RELEASE: Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics

Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche announced today licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Read more...

Get more Roche coverage at: